ACRS News & Events

Aclaris Therapeutics announced recent positive preclinical results from its potent and selective ITK/JAK3 inhibitor ATI-2138 in a murine model of severe alopecia areata. In this model of hair loss, conducted by Dr. Angela Christiano at Columbia University, ATI-2138 demonstrated rapid, near complete, and sustained hair regrowth compared to control and ritlecitinib.

Aclaris Therapeutics announced that it has initiated a placebo-controlled Phase 1b proof-of-concept trial in atopic dermatitis for ATI-052, the company's potential best-in-class investigational bispecific anti-TSLP/IL-4Ralpha antibody. "We are experiencing strong momentum in the ATI-052 clinical development program including the recent positive Phase 1a interim results which demonstrated a strong safety and tolerability profile, extended pharmacokinetics, and concentration-dependent pharmacodynamics even at the lowest dose," said Dr. Jesse Hall, Chief Medical Officer of Aclaris. "Further to this, we are excited to announce the initiation of the first POC Phase 1b trial in people living with atopic dermatitis. We expect to initiate the second Phase 1b POC trial in asthma this quarter as well. We intend to provide top line results from both trials in the second half of the year."

Aclaris Therapeutics announced positive interim results from the first-in-human Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4Ralpha bispecific antibody ATI-052. "Aclaris has experienced significant momentum across our pipeline over the past few months; consistent with that strong momentum, we are pleased to report positive interim results from our Phase 1a SAD/MAD trial of ATI-052 that exceeded our expectations," said Dr. Neal Walker, Chief Executive Officer of Aclaris. "ATI-052 demonstrated a strong safety and tolerability profile, dose proportional pharmacokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose - all of which support its best-in-class potential in a variety of inflammatory and immunological diseases due to its ability to uniquely impact multiple pathways of inflammation."